ClinicalTrials.gg
CompletedNCT04652882Updated Oct 9, 2026

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

A Phase 3 interventional study of Tasimelteon and Placebo in Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm and Chronobiology Disorders, sponsored by Vanda Pharmaceuticals. Completed at 17 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionSleep Disorders, Circadian RhythmRegistry: Sleep Wake DisordersReclassifiedWhy we changed it
Registry
Sleep Wake Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Disorders, Circadian Rhythm
Why
  1. The study's listed conditions name Sleep Disorders, Circadian Rhythm, a narrower term within Sleep Wake Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States — 10 open to participants now, 10 under way, 1 of them phase 3. Sleep Disorders, Circadian Rhythm · United States.

Enrollment
32nd of 54
43 · median 50
Started
2020
with 2 others
Phase 3
10 of 69
1 open now
Registered
50th of 69
by date
Lead sponsor
6 of 69
Vanda Pharmaceuticals

Among the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, this one is the 32nd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2020, is one of 10 in phase 3, and was the 50th registered.

Sleep Disorders, Circadian Rhythm

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

Browse Sleep Disorders, Circadian Rhythm studies →

Open to participants now

10 of the 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Sleep Disorders, Circadian Rhythm studies recruiting now, 7 (50%) set no upper age limit and 4 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Sleep Disorders, Circadian Rhythm with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.

03

Conditions studied

  • Sleep Wake Disorders
  • Sleep Disorders, Circadian Rhythm
  • Chronobiology Disorders

Browse trials for

04

In context

Sleep Disorders, Circadian Rhythm Reclassified

135 studies on the registry are indexed under Sleep Disorders, Circadian Rhythm; 25 are open to participants now.

This study's enrollment of 43 is below the median of 59 across 102 interventional studies indexed under Sleep Disorders, Circadian Rhythm.

Browse Sleep Disorders, Circadian Rhythm studies →

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Compared within Sleep Disorders, Circadian Rhythm, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Wake Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and acceptance to provide written .
  • A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
  • Men or women between 18 - 75 years, inclusive.
  • (BMI) of ≥ 18 and ≤ 35 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months.
  • Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
  • Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
  • A positive test for substances of abuse.
  • Current tobacco user.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Tasimelteon

    Drug: Tasimelteon

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Change in Sleep Onset over the treatment period, as measured by sleep diary.

    Time frame: 28 days

Secondary outcomes

  1. Change in nighttime objective sleep-wake parameters such as sleep time, as measured by actigraphy.

    Time frame: 28 days

  2. Change in nighttime subjective sleep-wake parameters such as sleep time, as measured by sleep diary.

    Time frame: 28 days

  3. Assessment of safety and tolerability of daily single dose of tasimelteon, as measured by spontaneous reporting of adverse events (AEs).

    Time frame: 28 days

08

Study locations

17 sites
  • Vanda Investigational Site
    Los Angeles, California 90025, United States
  • Vanda Investigational Site
    Redwood City, California 94063, United States
  • Vanda Investigational Site
    Aurora, Colorado 80045, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02115, United States
  • Vanda Investigational Site
    St Louis, Missouri 63123, United States
  • Vanda Investigational Site
    New Hyde Park, New York 11042, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45212, United States
  • Vanda Investigational Site
    Cleveland, Ohio 44195, United States
  • Vanda Investigational Site
    Columbia, South Carolina 29201, United States
  • Vanda Investigational Site
    San Antonio, Texas 78229, United States
  • Vanda Investigational Site
    Sherman, Texas 75092, United States
  • Vanda Investigational Site
    Innsbruck, 6020, Austria
  • Vanda Investigational Site
    Vienna, 1090, Austria
  • Vanda Investigational Site
    Berlin, 10117, Germany
  • Vanda Investigational Site
    Hamburg, 20253, Germany
  • Vanda Investigational Site
    Marburg, 35043, Germany
  • Vanda Investigational Site
    Schwerin, 19053, Germany
09

References and documents

Publications

  • Smieszek SP, Kaden AR, Johnson CE, Brzezynski JL, Xiao C, Polymeropoulos CM, Birznieks G, Emsellem HA, Polymeropoulos MH. Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study. Front Neurosci. 2023 Nov 14;17:1287514. doi: 10.3389/fnins.2023.1287514. eCollection 2023. PubMed 38033548 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Sep 2026, 68 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Dec 3, 2020
StartActual
Dec 9, 2020
Primary completionActual
Sep 4, 2026
CompletionActual
Sep 4, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Enrollment
70 (estimated)→43 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Enrollment 70 (estimated)→43 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04652882
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Dec 9, 2020
Primary completion
Sep 4, 2026
Completion
Sep 4, 2026
Last update
Oct 9, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion